Register entry
Liquidia Corporation
- Registered sites
- 1
- Drug products
- 4
- Live patents
- 24
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingFinished drug manufacture
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Liquidia Technologies, Inc. | Morrisville, NCUnited States | Analytical testing, Finished drug manufacture | 3008731457 |
Exclusivity
Patents
24Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| YUTREPIA | TREPROSTINIL SODIUM | May 2037 |
Catalogue
Marketed products
4Showing 4 of 4.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Yutrepia | treprostinil | CAPSULE | NDA |
| Yutrepia | treprostinil | CAPSULE | NDA |
| Yutrepia | treprostinil | CAPSULE | NDA |
| Yutrepia | treprostinil | CAPSULE | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.